Bairen Medical (688198.SH) 2023 equity distribution: 0.80 yuan per share, share registration on May 27

Bairen Medical (688198.SH) issued the 2023 equity distribution implementation notice. This time, profits are distributed to Israel...

Zhitong FinanceMay 20 08:24 ET

Bairen Healthcare (688198.SH): Net profit of 8.319,800 yuan in the first quarter decreased by 28.88% year-on-year

Gelonghui, April 22丨Bairen Healthcare (688198.SH) released its report for the first quarter of 2024. Operating revenue for the reporting period was 76.265,200 yuan, up 17.53% year on year; net profit attributable to shareholders of listed companies was 8.3198 million yuan, down 28.88% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 6.3778 million yuan, down 29.26% year on year; basic earnings per share were 0.06 yuan.

Gelonghui FinanceApr 22 03:54 ET

Zhongtai Securities: Edward Evoque received FDA approval and continues to be optimistic about the commercialization prospects of tricuspid valve intervention

Recently, Edward Life Sciences announced that its tricuspid valve product Evoque has been approved by the FDA for marketing. This is the first FDA-approved tricuspid valve replacement product.

Zhitong FinanceMar 1 02:54 ET

Bairen Healthcare (688198.SH): Net profit increased 20.99% year-on-year in 2023

Gelonghui, Feb. 27丨Bairen Medical (688198.SH) announced its 2023 annual performance report. During the reporting period, the company achieved annual revenue of 37,08549 million yuan, an increase of 25.64% over the previous year. The company's revenue in all three business segments achieved year-on-year growth: the heart valve replacement and repair segment increased 21.10% year on year, with artificial biological heart valve revenue increasing 27.74% year on year; the congenital heart implant interventional treatment and surgical soft tissue repair segment increased 26.88% and 29.74% year on year, respectively. The company achieved operating profit of 121.368 million yuan during the reporting period

Gelonghui FinanceFeb 27 04:59 ET

[BT Financial Report Momentary Analysis] Bairen Medical's 2023 Third Quarter Report: Steady Growth Shows Steady Growth, R&D Investment Continues to Increase

Beijing Bairen Medical Technology Co., Ltd. (stock code: 688198) recently released its financial report for the third quarter of 2023. As a domestic technology-leading research and development platform enterprise for animal-derived implant interventional medical devices, its steady growth trend is once again reflected. During the reporting period, in the context of facing multiple challenges in the market, the company still achieved steady growth in operating income and improvement in profitability, while continuing to increase investment in R&D and strengthen technology and product advantages. In terms of assets and liabilities, as of the end of the reporting period, the company's total assets reached 1,266 billion yuan, an increase of 7.36% over the end of the previous year, showing

businesstimes cnFeb 22 04:49 ET

Bairen Medical (688198.SH): Mitral valvuloplasty ring products approved for registration

Bairen Medical (688198.SH) issued an announcement. Recently reviewed by the State Drug Administration, the company independently developed...

Zhitong FinanceDec 21, 2023 02:45 ET